UBS Group
ONC

UBS Group’s BeOne Medicines Ltd ONC Stock Holding History

UBS Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,500
Closed -$1.75M – 8261
2018
Q4 		$1.75M Buy
+12,500
New +$1.66M ﹤0.01% 3160

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group's ONC Position: Q2 2026 in Review

UBS Group reduced its BeOne Medicines Ltd (ONC) stake by 38% in Q2 2026, selling an estimated $46.2M and leaving 258,589 shares worth $73.7M. The position accounts for 0.01% of the portfolio, ranked #1370.

UBS Group first reported a position in ONC in Q1 2016 and has held it in 40 quarters since. The position peaked at $123M in Q1 2026. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • UBS Group held 258,589 shares of BeOne Medicines Ltd worth $73.7M as of Q2 2026.
  • UBS Group sold 156,741 BeOne Medicines Ltd shares in Q2 2026, an estimated $46.2M.
  • BeOne Medicines Ltd made up 0.01% of UBS Group's portfolio in Q2 2026, its #1370 holding.
  • UBS Group first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 40 quarters since.
  • UBS Group's BeOne Medicines Ltd position peaked at $123M in Q1 2026.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.